Therapy Areas
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
25 March 2020 - - The US Food and Drug Administration has provided Emergency Use Authorization for US-based PerkinElmer, Inc.'s (NYSE: PKI) New Coronavirus RT-PCR test, the company said.

Clinical laboratories certified under Clinical Laboratory Improvement Amendments can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19.

PerkinElmer's RT-PCR test is marketed as an in vitro diagnostic device by meeting the requirements of the European In Vitro Diagnostic Directive and is available in over 30 countries worldwide.

PerkinElmer offers solutions to serve the diagnostics, life sciences, food and applied markets.

The company reported revenue of approximately USD 2.9bn in 2019, serves customers in 190 countries, and is a component of the S and P 500 index.


Related Headlines